Boubaddi Mehdi, Marichez Arthur, Pecquenard Florian, Maulat Charlotte, Buc Emmanuel, Sulpice Laurent, Ayav Ahmet, Truant Stéphanie, Muscari Fabrice, Chiche Laurence, Laurent Christophe
Hepatobiliary and Pancreatic Surgery Department, CHU de Bordeaux, Pessac, France.
Hepatobiliary and Pancreatic Surgery Department, CHU de Lilles, Lille, France.
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):937-949. doi: 10.21037/hbsn-24-315. Epub 2024 Nov 5.
Post-hepatectomy liver failure (PHLF) is the first cause of death after major hepatectomy, and future liver remnant (FLR) volume is the main factor predicting PHLF. Liver venous deprivation (LVD) via portal and hepatic vein embolization has been suggested to induce a better hypertrophy of the FLR than portal vein embolization. The aim of this retrospective multicentric study was to assess safety, feasibility and efficacity of LVD in a French national multicentric register.
Between 2016 and 2023, LVD was performed in 7 expert centers, for patients with liver malignancies requiring major hepatectomy with an FLR percentage of total liver volume (FLR%) ≤25% for a healthy liver or <30% for a diseased liver. FLR volumetry was assessed before and 4 weeks after the procedure.
One hundred and ninety-two patients were included in the study. The technical success rate was 100% and severe complication rate post-LVD was 2.6% (5/192). The FLR% increased by 61.7% over an average of 27±9.7 days. Major hepatectomy was performed 40 days after LVD on 161 (83.8%) patients. Hepatectomy was not performed on 31 (16.2%) patients, mostly because of oncological progression. Severe postoperative complications (Clavien-Dindo grade ≥ IIIA) occurred in 21.1% (34/161) of patients. Postoperative mortality rate was 4.3% (7/161).
This study is the largest to confirm that LVD is a safe, reproducible, efficient technique that induces rapid major FLR growth. However, this new technique needs to be standardized and harmonized between centers to ensure uniform results.
肝切除术后肝衰竭(PHLF)是大型肝切除术后的首要死亡原因,而未来肝残余量(FLR)是预测PHLF的主要因素。通过门静脉和肝静脉栓塞进行肝静脉剥夺(LVD)已被认为比门静脉栓塞能更好地诱导FLR肥大。这项回顾性多中心研究的目的是在法国国家多中心登记处评估LVD的安全性、可行性和有效性。
2016年至2023年期间,7个专家中心对需要进行大型肝切除术的肝恶性肿瘤患者进行了LVD,对于健康肝脏,FLR占全肝体积的百分比(FLR%)≤25%,对于患病肝脏,FLR%<30%。在手术前和手术后4周评估FLR体积。
192例患者纳入研究。技术成功率为100%,LVD术后严重并发症发生率为2.6%(5/192)。FLR%在平均27±9.7天内增加了61.7%。161例(83.8%)患者在LVD后40天进行了肝切除术。31例(16.2%)患者未进行肝切除术,主要原因是肿瘤进展。21.1%(34/161)的患者发生了严重术后并发症(Clavien-Dindo分级≥IIIA)。术后死亡率为4.3%(7/161)。
本研究是最大规模的研究,证实LVD是一种安全、可重复、有效的技术,可诱导FLR快速显著生长。然而,这项新技术需要在各中心之间进行标准化和统一,以确保结果的一致性。